Fundraising Fox
RiverVest Venture Partners
Venture capitalSt. Louis · Seed–Growth · 27 people tracked
Also known as RiverVest Venture · RIVERVEST VENTURE MANAGEMENT LLC
Find your way into RiverVest Venture Partners
Sign up to see every warm intro you have to RiverVest Venture Partners
- Paths you didn't know you had: your email and LinkedIn already hold routes to the RiverVest Venture Partners team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
RiverVest Venture Partners is a life-science venture capital firm concentrating on medical device and biopharmaceutical investments. Since its founding it has backed early-stage and later-stage companies, often co-founding and seed-funding businesses to position them for subsequent financing rounds and commercial success. The firm emphasizes integrity, discipline, teamwork and trust, and has originated numerous commercialized products that have treated millions of patients. Over its history it has raised multiple core funds plus specialized vehicles such as the 3x5 Special Opportunity Funds and the Archer Seed Fund, generating a strong track record of profitable exits via acquisitions and IPOs.
Source: firm website, verified Oct 17, 2026.
Team · 27 people
from the firm's website & public directoriesCo-founder of RiverVest who helped establish the firm's ethos of integrity, discipline, teamwork and trust. He passed away after decades of corporate and civic leadership.
Co-founder of RiverVest and co-founder of portfolio company Salient Surgical.
Co-founder of RiverVest who, with Andy Craig, explored the feasibility of a St. Louis-based venture capital firm.
Nicholas Walrod is Managing Partner of the Private Investments Team at American Century Investments, an asset management firm. He has more than 20 years of work experience in venture capital, with a focus on strategy, start-ups, and entrepreneurship. Before joining American Century Investments, he co-founded and led 503 Partners, a Portland, Oregon–based venture capital firm focused on the life science sector and resource-driven areas including water, agriculture, energy, and natural resources.
Joined RiverVest's investment team.
Joined when the Cleveland office opened, improving the firm's deal flow and due diligence resources, and was later promoted to managing director.
Joined RiverVest and helped develop its successful biopharma strategy.
Nafise Masoumi is a Principal at RiverVest Venture Partners, a life science venture fund investing in biotech and medtech companies across private and public markets from early to late stage, where she leads diligence activities. She previously worked as a senior associate at Novo Ventures and as a consultant in the healthcare practice at Boston Consulting Group, and earlier held research roles at the Cardiac Surgery Department of Boston Children's Hospital, Harvard Medical School, and in Prof. Langer's lab at the Koch Institute at MIT. Masoumi holds a B.Sc. and M.Sc. in Chemical Engineering and a Ph.D. in Biomedical Engineering.
Joined RiverVest and was later promoted to principal.
Courtney Harris is Controller at RiverVest Venture Partners. Harris has worked in the venture capital and private equity industry, with experience in financial accounting, due diligence, variance analysis, financial analysis, and small business operations.
Joined RiverVest to advise on medical device investments and connect the firm to the innovation community in Israel.
Andrew Kleiboeker joined RiverVest as an analyst in 2020, was promoted to senior analyst in 2022 and associate in 2024. He supports due diligence on medical device investments and performs financial analysis for portfolio financings and M&A, and holds a board observer seat at InterVene Medical. He earned a B.S. in Business Administration summa cum laude from Washington University in St. Louis.
Sivan Weitzman joined RiverVest in 2019 as CFO, overseeing the firm's financial operations across its funds, portfolio investments, and management company. She previously served as CFO at Halman Aldubi Investment House in Tel Aviv and spent four years as an audit and assurance senior manager at Deloitte.
What they invest in
from 52 of 103 portfolio companiesBiotech ×39Healthtech ×28Medical Devices ×19Digital Health ×6Enterprise Software ×4Hardware ×3SaaS ×3AI & Machine Learning ×2
HQs:United States×42Germany×1Mexico×1Vietnam×1
Who they back
founder profiles across 17 portfolio companiesFounding team size:solo founder×142 founders×24+ founders×1
Investments · 103 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 52024 · 22023 · 32022 · 12021 · 42020 · 42019 · 22018 · 32017 · 32016 · 32015 · 242 dated
Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).
BiotechHealthtechSouth San Francisco, US
Samir Gharib(Executive Officer)inRICHARD KING(Executive Officer, Director)inJavier Szwarcberg(Chief Executive Officer)in
BoardSimpson Camilla(Director)Tiba Aynechi(Director)inBali Muralidhar(Director)in
Board seatNiall O'Donnell· per SEC Form D
Co-investorsAisling CapitalHealthCapAbingworthNorwest Venture PartnersNovo HoldingsOmega Funds+1 more
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersPivotal Life Sciences+9 more
MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients.
BiotechHealthtechMedical Devices
Scott Koenig(Director)inEric Risser(President and Chief Executive Officer)in
Co-investorsHavencrest Capital ManagementRidgeback CapitalSaints CapitalSanofi VenturesLa CaisseTPG
Mirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases.
BiotechHealthtechSan Diego, US
Chris Peetz(Co-founder & Chief Executive Officer)inEric Bjerkholt(Executive Officer)inPeter Radovich(Executive Officer)in
BoardPatrick Heron(Director)inMichael Grey(Director)Timothy Walbert(Director)
Co-investorsChiesi VenturesFrazier Life SciencesLongitude CapitalMESA VERDE VENTURE PARTNERSNew Enterprise Associates (NEA)Pappas Capital+4 more
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies.
BiotechDigital HealthHealthtechMedical DevicesBoulder, US
Jason Leverone(Executive Officer)inSamuel Agresta(Executive Officer)inDylan Hartley(Executive Officer)inWendy Johnson(Executive Officer)Nicholas A. Saccomano(President and Chief Executive Officer and Director)
BoardIsaac Manke(Director)in
Co-investorsAccess BiotechnologyBoulder VenturesAbingworthACORN BIOVENTURESNew Enterprise Associates (NEA)Novo Holdings
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.
BiotechHealthtechWaltham, US
René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)inKatarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)
Co-investorsBain Capital Life SciencesBay City CapitalF-Prime CapitalM VenturesMRL Ventures FundRA Capital+9 more
Biolinq develops glucose-sensing technology based on micro-array biosensors for metabolic health monitoring, including continuous glucose monitoring.
BiotechDigital HealthHardwareHealthtechMedical DevicesSan Diego, US
Jared Tangney(Co-founder)inRich Yang(Co-founder)inEdward Kliphuis(Director)
BoardDaniel Bradbury(Director)inLana Ghanem(Director)
Co-investorsAlpha Wave GlobalAble PartnersAphelion CapitalAverin CapitalBeyond CapitalBioBrit+7 more
Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.
BiotechDigital HealthMedical DevicesSan Diego, US
Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)inVikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)
Co-investorsForesite CapitalLongwood FundNorwest Venture PartnersPivotal Life SciencesYsios Capitalabrdn plc+4 more
Alleviant Medical develops an investigational minimally invasive medical device using interatrial shunt therapy to treat heart failure patients, currently in FDA-approved clinical trials (ALLAY-HF and ALLAY-HFrEF).
BiotechHealthtechMedical DevicesAustin, US
Adam Berman(Executive Officer, Director)inJacob Kriegel(Executive Officer, Director)Avni Patel(Executive Officer, Director)Christopher Alex Arevalos(Executive Officer, Director)Albertien Greijdanus(Executive Officer, Director)
BoardGeoff Pardo(Director)in
Board seatJay Schmelter· per SEC Form D
Co-investorsBroadview VenturesTMC Venture FundCadence Healthcare VenturesGilde HealthcareGilmartin Capital LLCOmega Funds+2 more
Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity.
BiotechHealthtechSeattle, US
John Mulligan(Executive Officer, Director, Promoter)inNeela Patel(Executive Officer)inDiane Hollenbaugh(Executive Officer)in
BoardSamuel Bjork(Director)inMonique Schiersing(Director)in
Board seatJohn McKearn· per SEC Form D
Co-investorsRoche Venture FundVivo Capital3x5 PartnersCodon CapitalDigitalis Ventures
Developing implantable low-energy pain-free atrial cardioverters for atrial fibrillation.
HealthtechSt. Louis, US
M. Brent Shelton(Executive Officer)Paula Skjefte(Executive Officer, Director)Nick Lanners(Executive Officer)Igor Efimov(Director)
BoardEric A. Gulve(Executive Officer, Director)Warren Watson(Director)
Board seatJay Schmelter· per SEC Form D
Co-investorsBroadview VenturesCultivation Capital
Avalyn Pharma (formerly Genoa Pharmaceuticals) is a biopharma company developing inhaled therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases.
BiotechHealthtechSan Diego, US
Mark W. Surber, Ph.D.(Executive Officer, Director)Richard G. Vincent(Executive Officer)
BoardMichael J. Kamdar(Director)Daniel D. Burgess(Director)
Board seatNiall O'Donnell· per SEC Form D
Co-investorsF-Prime CapitalNorwest Venture PartnersSofinnova Ventures
Portfolio company acquired by Roche.
BiotechSeattle, US
John Mulligan(Executive Officer, Director, Promoter)inMitchell Mutz(Director)Nicholas Walrod(Director)
BoardKarl Handelsman(Director)
Board seatJohn McKearn· per SEC Form D
Co-investorsDigitalis VenturesRoche Venture Fund3x5 PartnersCodon Capital
InterVene, Inc. is a medical device company that has developed a fully integrated mechanical thrombectomy system to treat venous in-stent restenosis and residual thrombotic venous obstructions and occlusions.
BiotechHealthtechMedical DevicesMountain View, US
Fletcher Wilson(Executive Officer, Director)in
BoardThomas Fogarty(Director)Mel Schatz(Director)
Board seatJay Schmelter· per SEC Form D
Co-investorsLaunchCapitalTreo Ventures, LlcEmergent Medical Partners, LLP
Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.
BiotechHouston, US
Alice Bexon(Executive Officer)inClifford J. Stocks(Director, Executive Officer)inKamal D. Puri(Executive Officer)inChris Russell(Executive Officer)inRuss Hawkinson(Executive Officer)
BoardSteven Gillis(Director)in
Board seatJohn McKearn· per SEC Form D
Co-investors3B Future Health FundCanaan PartnersGreatPoint VenturesAlexandriaARCH Venture PartnersBering Capital+5 more
Smart Wires provides advanced power flow control technology for electric utilities and transmission operators, letting them redirect electricity away from constrained circuits to increase usable transfer capacity and strengthen grid reliability.
CleantechEnergyHardwareOakland, US
James C David(Executive Officer, Director)Woody Gibson(Executive Officer)Stewart Ramsay(Executive Officer, Director)
BoardAnthony Arnerich(Director)Frederick Buckman(Director)
Board seatJay Schmelter· per SEC Form D · $85.8M raise · filed Jan 2020
Co-investorsAlumni VenturesEnergy Transition Ventures3x5 Partners
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cardiometabolic disease.
BiotechHealthtechMedical DevicesPortland, US
Robert Jacks(Executive Officer, Director)inDavid Aaron Katz(Executive Officer, Director)
BoardJonathan Root(Director)inZach Scheiner(Director)inKlaus Veitinger(Director)in
Board seatNiall O'Donnell· per SEC Form D
Co-investorsOrbiMedRA CapitalUS Venture PartnersForbion
Allotera (formerly Wugen) develops allogeneic T-cell therapies.
BiotechHealthtechMedical DevicesSt. Louis, US
Ayman Kabakibi(Executive Officer)inCherry Thomas(Executive Officer)inKumar Srinivasan(Executive Officer, Director)inKeith Vendola(Executive Officer)Daniel M Kemp(Executive Officer, Director)Matthew Cooper(Executive Officer)
Board seatNiall O'DonnellJohn McKearn· per SEC Form D
Co-investorsAisling CapitalAlpha Wave GlobalBioGenerator VenturesAbingworthFidelity InvestmentsIntermediate Capital Group+1 more
Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.
BiotechSan Carlos, US
Nenad Tomasevic(Executive Officer)Christopher Bebbington(Executive Officer, Director)Alejandro Dorenbaum(Executive Officer)
BoardFarah Champsi(Director)inJohn McKearn(Director)inPeter Moldt(Director)
Co-investorsAlta PartnersLifeSci Venture PartnersNew Enterprise Associates (NEA)Roche Venture FundSamsara BioCapital
St. Louis, US
Co-investorsAisling CapitalBioGenerator VenturesLYZZ CapitalAbingworth
Developing a new class of antifungal medicine to overcome limitations of current therapies.
Co-investorsBioBritGolden SeedsKeiretsu ForumPappas CapitalSofinnova Ventures3x5 Partners+4 more
Pfizer discovers, develops, manufactures, and distributes pharmaceutical medicines and vaccines across therapeutic areas including oncology, cardiology, immunology, and infectious diseases.
BiotechHealthtechMedical DevicesNew York, US
Charles Pfizer
Co-investorsAisling CapitalAndera PartnersRho Capital PartnersRho VenturesVenrockNew Enterprise Associates (NEA)
AnTolRx develops immunotherapy therapeutics based on research in immune tolerance, targeting immune-mediated disorders.
BiotechHealthtechBoston, US
Francisco J. Quintana(Scientific Founder, Member of Board of Directors)Mark Carthy(Founder and CEO, Member of Board of Directors)
BoardSatish Jindal(Director)
Co-investorsAvego BioScience CapitalBioGenerator VenturesPerot JainRoche Venture FundSR One Capital Management
Arexera Therapeutics, formerly Atalanta Therapeutics, is a biotechnology company developing small interfering RNA (siRNA) medicines to treat severe neurological diseases, with a franchise focused on Huntington's disease.
BiotechLongevity
Atalanta is developing treatment options for intractable central nervous system diseases using RNA interference technology.
BiotechDeep TechHealthtechMedical Devices
Co-investorsF-Prime CapitalNovartis Venture FundSanofi Venturesabrdn plcEQT Life Sciences
Biogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology.
BiotechMedical Devices
Charles Weissmann(Founder)Kenneth Murray(Founder)Phillip Sharp(Founder)Walter Gilbert(Founder)
Co-investorsAlpha Wave GlobalAsset Management CompanyKleiner Perkins
Bluejay develops tools for improving the reliability of generative AI systems in production environments.
AI & Machine LearningDeveloper ToolsEnterprise SoftwareSan Francisco, US
Rohan Vasishth(CEO)inFaraz Siddiqi(CTO)in
Co-investorsAntigravity CapitalEight CapitalFloodgateHomebrewMoonlanding VenturesY Combinator+6 more
Bluejay is a biotechnology company focused on therapeutic development.
BiotechSan Mateo, US
Keting Chu(Founder, Chief Executive Officer and Chairman of the Board)inDajun Yang(Director)Nancy Hong(Director)inAlon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)
Co-investorsFrazier Life SciencesRA CapitalWellington ManagementFrazier Healthcare PartnersHBM Healthcare InvestmentsNovo Holdings+2 more
Lifepoint is a diversified healthcare delivery network operating community hospitals, rehabilitation and behavioral health hospitals, and additional sites of care across the healthcare continuum.
Digital HealthHealthtech
Scott Mercy(Founding Chairman and CEO)
Co-investorsBaird CapitalRC Capital
Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Lou Lange(Founder)Michael L. Riordan(Founder)inDaniel O'Dayin
Co-investorsAisling CapitalAsset Management CompanyFrazier Life SciencesKleiner PerkinsLongitude CapitalLumira Ventures+6 more
Captisol is a pharmaceutical-grade sulfobutylether beta-cyclodextrin (SBECD), a derivatized beta cyclodextrin used to solubilize and stabilize difficult-to-deliver molecules across routes such as parenteral, oral, ophthalmic, nasal, and inhalation.
BiotechHealthtechNew Materials
Medtronic designs and develops medical technology for treating complex diseases.
AI & Machine LearningDigital HealthHealthtechMedical Devices
Co-investors8VCCWRU Technology VenturesElevate VenturesMenlo VenturesOak Investment PartnersPfizer Venture Investments+5 more
FLEX Vascular develops endovascular devices for treating stenoses in arteriovenous fistulas, grafts, and peripheral vascular conditions.
BiotechHealthtechMedical Devices
John P. Pigott(Founder, Advisor)John P. Pigott, MD(Founder, Advisor)
Co-investorsS3 Ventures
Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.
BiotechHealthtechMedical DevicesNew York, US
Co-investorsBrandon CapitalKleiner PerkinsNew Enterprise Associates (NEA)Nextech InvestProspect Venture PartnersRho Capital Partners+3 more
Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.
BiotechSan Francisco, US
Agnes Rafalko(Executive Officer, Director)inSteven Axon(Chief Executive Officer)inHicham Alaoui(Chief Scientific Officer)inRose Marino(Chief Medical Officer)inPeter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)in
Co-investorsAdvent Life SciencesAsahi Kasei Corporate Venture CapitalChiesi VenturesCTI Life Sciences Fund L.P.Mission Bay CapitalMission Biocapital+6 more
Acquired by Shire in 2014 (now part of Takeda).
BiotechMedical DevicesDurham, US
John McKearn(Director)Edward E. Greene(Director)Rosina Maar Pavia(Director)Ford S. Worthy(Executive Officer)Michael Grey(Executive Officer, Director)
Co-investorsFrazier Life SciencesLongitude CapitalOberland CapitalPappas CapitalSanofi Ventures
Maxwell Biomedical develops a device-based alternative to catheter ablation for atrial fibrillation, using closed-loop adaptive left atrial multisite pacing and Spatial Resynchronization Therapy (SRT) to terminate AF without high-energy shock.
BiotechHardwareHealthtechMedical Devices
Randy Werneth(CEO, President)inTimothy Corvi(Sr. VP, R&D)inDerrick Chou(VP, Science & Technology)
Co-investorsBroadview Ventures
Neuros Medical develops the Altius Direct Electrical Nerve Stimulation System, an FDA-approved implantable device that delivers patient-controlled electrical stimulation to treat chronic post-amputation pain in adult lower limb amputees.
BiotechHealthtechMedical DevicesAliso Viejo, US
David Veino(President and CEO)Zach Stassen(Chief Financial Officer)Robert J. Centa(Chief Financial Officer)Jon J. Snyder(Director, President, Secretary and CEO)in
BoardJoyce Erony(Director)inWilliam Harrington(Director)in
Co-investorsAmzak HealthAPERTURE Venture PartnersCWRU Technology VenturesiSelect FundJobsOhio VenturesJumpstart Ventures+5 more
Reneo is an asset and investment management platform for decarbonizing residential real estate portfolios in Germany.
Climate TechEnterprise SoftwarePropTechGermany, DE
Lennart Börner(Founder & Co-CEO)inAlexander Graubner-Müller(Founder & Co-CEO)in
Co-investorsFoundamentalAbingworthAisling CapitalAmzak HealthEurazeoLakestar+4 more
Xoilac TV is a free online football (soccer) live-streaming platform serving fans in Vietnam, offering Full HD match broadcasts of European, Asian, Vietnamese, and international competitions.
ConsumerMedia & EntertainmentSports Tech
Co-investorsAisling CapitalNew Enterprise Associates (NEA)Pappas CapitalAbingworthAmzak HealthLundbeckfonden Ventures+2 more
Scout Bio developed biotechnology therapies for pets, including a pipeline of monoclonal antibodies and gene therapy programs targeting chronic diseases in companion animals.
AgTechBiotechDeep TechHealthtechPhiladelphia, US
Mark Hefferman(Executive Officer, Director)
BoardAditya Kohli(Director)inTadataka Yamada(Director)Patrick Heron(Director)inCindy Cole(Director)inNancy Hong(Director)
Co-investorsCompanion FundCorrelation VenturesDigitalis VenturesFrazier Life Sciences
BiotechWaltham, US
Ellen E. Sheets(Executive Officer, Director)in
BoardCarl M. Berke(Director)inNancy Hong(Director)in
Co-investorsBold Capital PartnersDigitalis VenturesKdT Ventures
ShareFile provides secure file sharing, document collection, e-signature capabilities, and automated workflow management for teams collaborating with clients, partners, and vendors.
Enterprise SoftwareSaaS
Co-investorsAstellaBlack Diamond VenturesBrightstone Venture CapitalCID CapitalConcord Health PartnersH Venture Partners+1 more
Standard Bariatrics develops the Titan SGS™ Stapler, a specialized surgical device designed for sleeve gastrectomy procedures that creates consistent and symmetrical gastric pouches using an anatomy-based approach.
Medical Devices
Co-investorsArieal Southeast Angel PartnersCincyTechEmergent Medical Partners, LLPHatteras Venture PartnersJobsOhio VenturesRC Capital+2 more
Statcounter provides website analytics and visitor tracking software that displays traffic data, user behavior, and engagement metrics in a simple interface.
AdTechData & InfrastructureMarketing TechSaaS
Aodhán Cullen(Founder and CEO)in
Co-investorsGabriel Venture PartnersHomegrown CapitalHuangpu River CapitalIaso VenturesKumpulan Modal PerdanaNucleation Capital+2 more
WP Engine provides managed hosting and platform services for WordPress websites, serving companies and agencies of all sizes with infrastructure, tools, and support.
Cloud ComputingDeveloper ToolsEnterprise SoftwareSaaSAustin, US
Jason Cohen(Founder)inDavid Brolsma(Executive Officer)inHeather Brunner(Executive Officer)inChad Costello(Executive Officer)inRick Crandall(Director)Mariano Dima(Director)
Co-investorsAcario Innovationboldstart venturesCapital FactoryEquity Trust CompanyGolub GrowthHazelview Ventures+9 more
BiotechCoppell, US
Alvaro F. Guillem(Executive Officer, Director)Todd Creech(Executive Officer)Donald Jeffrey Keyser(Executive Officer, Director)Cynthia Smith(Executive Officer)Henrick Sandvad Rasmussen(Executive Officer)Robert Alexander(Executive Officer, Director)
Co-investorsSofinnova Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Adarza BioSystemsCurzion Pharmaceuticals IncLyric PharmaceuticalsTryton MedicalVasculoxVentureMed Group555 Bryant StreetAlleviantAlloteratxAmplyx PharmaceuticalsApnex MedicalArchArchmontArchmont Biopharma IncBlue Jay TherapeuticsBluejay TherapeuticsBridgePoint MedicalCabrellisCabrellis Pharmaceuticals CorporationCameron Health IncCGICgi Pharmaceuticals IncCodeable TherapeuticsConformaConforma Therapeutics CorporationCurzionCydexExcaliardExcaliard Pharmaceuticals IncGoodiDevIdev Technologies IncInterVene MedicalLumenaLutonixMirumMPEXMpex Pharmaceuticals IncMyonid TherapeuticsNeurosOtonomyOutriggerOxalurx IncProspex MedicalSalientSalient SurgicalSalient Surgical Technologies IncScoutBioSecurusSecurus Medical Group IncSparrow PharmaceuticalsUhcVelocimed LlcXilioZiarco
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 25
6 IPOs · 19 acquisitions · showing 20Spruce BiosciencesNASDAQ: SPRBAvalyn Pharma IncNASDAQ: AVLNMacrogenics IncNASDAQ: MGNXMirum PharmaceuticalsNASDAQ: MIRMOnkure Therapeutics IncNASDAQ: OKURXilio TherapeuticsNASDAQ: XLOCurzion Pharmaceuticals Incacq. by Horizon TherapeuticsGood Therapeuticsacq. by RocheBluejaytxacq. by Mirum PharmaceuticalsCabrellisacq. by PharmionCameron Health Incacq. by Boston ScientificEpix Therapeuticsacq. by MedtronicExcaliard Pharmaceuticals Incacq. by PfizerIdev Technologies Incacq. by AbbottLumena Pharmaceuticalsacq. by ShireLutonixacq. by C.R. Bard, Inc.Salient Surgicalacq. by MedtronicScout Bio Incacq. by Ceva Santé AnimaleSecurus Medical Group Incacq. by Boston ScientificVelocimed Llcacq. by St. Jude Medical
Portfolio news
latest coverage across their companies
Spruce Biosciences · stocktitan.net · Aug 12, 2026
Bluejay · finance.yahoo.com · Sep 26, 2025
Wugen · finsmes.com · Aug 28, 2025
Neuros Medical · finsmes.com · Jul 9, 2025
Bonum Therapeutics · biospace.com · Jun 10, 2025
IPO stake values · per SEC filings · 4
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Mirum Pharmaceuticals | 7.6% | $20.00 | Jan 2020 | $38.4M |
| Onkure Therapeutics Inc | 9.1% | $15.00 | Apr 2021 | $33.1M |
| Spruce Biosciences | 8.5% | $15.00 | Oct 2020 | $28.5M |
| Xilio Therapeutics | 4.5% | $16.00 | Oct 2021 | $19.1M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Public market activity · per SEC filings
what is this? ⓘDisclosed stake · filed Feb 2024
Disclosed stake · filed May 2023
Disclosed stake · filed May 2023
Disclosed stake · filed Apr 2021
Disclosed stake · filed Feb 2021
Disclosed stake · filed Jan 2021
Disclosed stake · filed Oct 2020
Disclosed stake · filed May 2020
Disclosed stake · filed Sep 2018
14 insider ownership filings (Forms 3/4/5)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has RiverVest Venture Partners made?
- RiverVest Venture Partners has 103 tracked investments, 25 of which have exited, including 6 dated in the last 24 months.
- What stage does RiverVest Venture Partners invest at?
- RiverVest Venture Partners invests at the Seed, Series A, Series B, Series C, Growth stages.
- What is RiverVest Venture Partners's typical check size?
- RiverVest Venture Partners typically writes checks of $500K – $3M.
- What sectors does RiverVest Venture Partners focus on?
- RiverVest Venture Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is RiverVest Venture Partners located?
- RiverVest Venture Partners is headquartered in St. Louis, US.
- Does RiverVest Venture Partners lead rounds?
- Yes, RiverVest Venture Partners leads investment rounds.
- Who does RiverVest Venture Partners co-invest with?
- RiverVest Venture Partners most often shares deals with New Enterprise Associates (NEA), Aisling Capital, Frazier Life Sciences, among 145 tracked co-investors.
Media · Podcasts & interviews
featuring the teamTom Melzer, Managing Director & Co-Founder, RiverVest Venture Partners
InvestMidwest Venture Capital (Forum) · Tom Melzer
Co-investors · 21
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Abingworth is a life science venture capital firm that backs early-stage biopharma and biotech companies, helping entrepreneurs translate scientific discoveries into new therapeutics.
Roche Venture Fund is the corporate venture arm of Roche, investing in life science companies across pharmaceuticals, diagnostics and digital health to foster innovation and generate financial returns.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies aligned with Sanofi's mission of advancing human health.
Digitalis Ventures invests in solutions to unmet needs in biomedicine and health, backing biotechnology and technology-enabled companies across human health and animal health.
S3 Ventures is a venture capital firm, founded over twenty years ago, backed by a single limited partner—a multi-billion dollar philanthropic family office foundation.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university research and breakthrough science.
SR One Capital Management is a life sciences venture firm that takes a back-and-build approach to investing in biotech and therapeutics companies, supporting entrepreneurs with human, intellectual, and financial resources.
Forbion is a global venture capital firm focused on advancing biotech innovations and other sustainable solutions aimed at improving human and planetary health.
Deerfield Management Company is a healthcare-focused investment firm, founded in 1994, that advances healthcare through investment, intelligence, and philanthropy.
▶9 more co-investors
Pivotal Life SciencesFrazier Healthcare PartnersCodon CapitalCanaan PartnersPolaris PartnersDomain AssociatesAdvent Life SciencesAlta PartnersUnknown Ventures
Firms observed investing alongside RiverVest Venture Partners, from public investor directories. Shared companies are the overlap with RiverVest Venture Partners's recorded portfolio.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is an independent manager of venture capital funds and the listed investment company Quest for Growth, backing innovative companies that use technology as a competitive advantage.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.